CASI Pharmaceuticals Discloses Material Development Relating To Its Dispute With Juventas
CASI Pharmaceuticals Discloses Material Development Relating To Its Dispute With Juventas
On April 8, 2024, CASI Pharmaceuticals, announced that, with respect to the Company's previously announced dispute with Juventas Cell Therapy Ltd., an emergency arbitrator appointed by the Hong Kong International Arbitration Centre (the "HKIAC") issued an Order on April 5, 2024, granting the emergency injunctive relief CASI sought pending the determination of the arbitration proceeding initiated with the HKIAC in connection with the dispute (the "Arbitration Proceeding"). The emergency arbitrator's Order, among other things, prohibits Juventas from commercializing CNCT19 by itself or through another third party. The emergency arbitrator also noted in the Order that the parties shall cooperate to reach a temporary arrangement that allows them to provide CNCT19 to new patients.
2024年4月8日，CASI制药宣布，关于公司先前宣布的与尤文塔斯细胞疗法有限公司的争议，香港国际仲裁中心（“HKIAC”）任命的紧急仲裁员于2024年4月5日发布命令，批准CASI寻求的紧急禁令救济，以待与香港国际仲裁中心启动的与该争议有关的仲裁程序（“仲裁程序”）作出裁决。。紧急仲裁员的命令除其他外，禁止尤文塔斯自行或通过其他第三方将 CNCT19 商业化。紧急仲裁员还在命令中指出，双方应合作达成临时安排，允许他们向新患者提供 CNCT19。